FDA ended June with 5 new approvals.*selinexor for r/r DLBCL*pembrolizumab for cutaneous squamous cell carcinoma*pembrolizumab for MSI-h/dMMR met. colorectal cancer*avelumab maintenance for met. bladder cancer*SC trastuzumab/pertuzumab/hyaluronidase